We partnered with Daiichi Sankyo and AstraZeneca on a pre-launch omnichannel program to raise awareness on the significant unmet clinical need and the promise of an emerging class of therapies (Antibody-Drug Conjugates) for the treatment of mNSCLC amongst Community Oncologists.
MoA
To increase digital reach and relevance to Academic Oncologists without MSL support, we developed a website and email marketing campaign with an innovative, neutral, and confident approach.
The awareness and education program included a series of Cancer Conversation videos and podcasts by KOLs and Community Oncologists, that were promoted through customized emails and social media posts.